IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 239 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83,612,751 | -30.1% | 18,376,429 | +8.1% | 0.00% | -33.3% |
| Q2 2023 | $119,692,608 | +57.3% | 17,001,791 | +36.5% | 0.00% | +50.0% |
| Q1 2023 | $76,110,206 | -1.4% | 12,456,662 | +3.1% | 0.00% | 0.0% |
| Q4 2022 | $77,172,682 | -29.7% | 12,077,102 | +5.3% | 0.00% | -50.0% |
| Q3 2022 | $109,849,000 | -14.0% | 11,466,492 | -0.9% | 0.00% | 0.0% |
| Q2 2022 | $127,744,000 | +3.3% | 11,571,066 | +55.8% | 0.00% | +33.3% |
| Q1 2022 | $123,692,000 | -12.5% | 7,428,992 | +0.3% | 0.00% | -25.0% |
| Q4 2021 | $141,427,000 | -17.5% | 7,408,505 | +6.6% | 0.00% | -20.0% |
| Q3 2021 | $171,333,000 | -2.7% | 6,947,806 | +2.7% | 0.01% | 0.0% |
| Q2 2021 | $176,107,000 | -38.0% | 6,768,169 | -24.6% | 0.01% | -37.5% |
| Q1 2021 | $284,140,000 | -32.0% | 8,974,815 | -0.3% | 0.01% | -38.5% |
| Q4 2020 | $417,719,000 | +38.8% | 9,002,588 | -1.6% | 0.01% | +18.2% |
| Q3 2020 | $301,050,000 | +13.2% | 9,144,915 | -5.6% | 0.01% | 0.0% |
| Q2 2020 | $265,992,000 | -10.2% | 9,690,080 | -2.1% | 0.01% | -21.4% |
| Q1 2020 | $296,322,000 | +11.6% | 9,898,874 | +3.2% | 0.01% | +40.0% |
| Q4 2019 | $265,579,000 | +54.2% | 9,594,660 | +1.4% | 0.01% | +42.9% |
| Q3 2019 | $172,204,000 | -24.9% | 9,461,777 | +1.1% | 0.01% | -30.0% |
| Q2 2019 | $229,410,000 | +173.0% | 9,355,972 | +5.9% | 0.01% | +150.0% |
| Q1 2019 | $84,026,000 | +8.1% | 8,835,527 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $77,706,000 | +3.8% | 8,780,191 | +32.0% | 0.00% | +33.3% |
| Q3 2018 | $74,858,000 | -7.1% | 6,653,978 | +5.7% | 0.00% | -25.0% |
| Q2 2018 | $80,598,000 | -17.5% | 6,296,691 | +8.9% | 0.00% | -20.0% |
| Q1 2018 | $97,747,000 | +151.2% | 5,783,847 | +18.9% | 0.01% | +150.0% |
| Q4 2017 | $38,918,000 | +12.5% | 4,864,841 | +9.0% | 0.00% | 0.0% |
| Q3 2017 | $34,589,000 | -22.4% | 4,463,098 | -26.4% | 0.00% | 0.0% |
| Q2 2017 | $44,581,000 | – | 6,065,434 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |